CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...